These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16201048)

  • 1. Antiretroviral rounds. Virologic failure: true or false?
    Gallant JE; Shafer R
    AIDS Clin Care; 2005 Sep; 17(9):84-5. PubMed ID: 16201048
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement in CD4+ cell counts despite persistently detectable HIV load.
    Levitz SM
    N Engl J Med; 1998 Apr; 338(15):1074-5. PubMed ID: 9537882
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antiretroviral therapy 1994 versus 2004. The reality illustrated by typical cases].
    Kuhlmann B; Trein A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():72-3. PubMed ID: 15373057
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antiviral therapy: when to begin, which goals should be set, what must be kept in mind? Tips for nonspecialists].
    Jablonowski H
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():10-1. PubMed ID: 16385862
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.
    Persaud D; Palumbo P; Ziemniak C; Chen J; Ray SC; Hughes M; Havens P; Purswani M; Gaur AH; Chadwick EG;
    J Infect Dis; 2007 May; 195(10):1402-10. PubMed ID: 17436219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV-1 intermittent drug intensification in HIV-1-infected patients naive for antiretrovirals.
    Rusconi S; Argenteri B; Galli M; d'Arminio-Monforte A; Moroni M
    Antivir Ther; 1999; 4(3):183-4. PubMed ID: 12731759
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral therapy in HIV/AIDS: update from San Francisco.
    Laurence J
    AIDS Read; 2000 Mar; 10(3):133-4. PubMed ID: 10758008
    [No Abstract]   [Full Text] [Related]  

  • 11. Questions about HIV causing AIDS? Viral load and T-cell (CD4) counts: why they really matter.
    AIDS Treat News; 2001 May; (364):7-8. PubMed ID: 11569964
    [No Abstract]   [Full Text] [Related]  

  • 12. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to highly active antiretroviral therapy.
    Zuger A
    AIDS Clin Care; 1997 Nov; 9(11):86-7. PubMed ID: 11364775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Viral load and monitoring of antiretroviral treatment].
    Soriano V; Mas A; Gómez-Cano M; Villalba N; Bravo R; González-Lahoz J
    Rev Clin Esp; 1996 Dec; 196(12):872-7. PubMed ID: 9132868
    [No Abstract]   [Full Text] [Related]  

  • 17. Rationale for early antiretroviral therapy in patients with CD4 cell counts > 500 cells/mm3.
    Soriano V; Gómez-Cano M; Mas A; Villalba N; Bravo R; González-Lahoz J
    Antivir Ther; 1996 Dec; 1(4):264-5. PubMed ID: 11324829
    [No Abstract]   [Full Text] [Related]  

  • 18. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.